Skip to main content
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd

$30.81 -0.37 (-1.19%) At close · Jul 24
Market Cap
$35.88B
Shares
1.16B

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Richard Francis $19,168,709
Evan Lippman $7,222,009
Eli Kalif $6,961,991
Dr. Eric A. Hughes $6,298,933
Christine Fox $5,895,161
Fiscal 2024
Executive Total
Richard Francis $15,518,947
Eli Kalif $6,175,059
Dr. Eric A. Hughes $5,754,787
Richard Daniell $5,433,292
Christine Fox $5,218,023
Fiscal 2023
Executive Total
Richard Francis $25,706,880
Richard Daniell $5,164,163
Eli Kalif $4,943,832
Mark Sabag $3,729,134
Fiscal 2022
Executive Total
Dr. Sven Dethlefs $4,063,280
Eli Kalif $4,014,617
Mark Sabag $3,923,933
Fiscal 2021
Executive Total
Dr. Sven Dethlefs $3,817,377
Mark Sabag $3,788,741
Eli Kalif $3,544,983
Fiscal 2020
Executive Total
Dr. Hafrun Fridriksdottir $4,290,333
Brendan O’Grady $4,126,283
Eli Kalif $3,723,815
Fiscal 2019
Executive Total
Dr. Hafrun Fridriksdottir $4,377,725
Dr. Carlo de Notaristefani $4,318,838
Michael McClellan $4,231,243
Brendan O’Grady $3,462,290
Eli Kalif $20,555
Fiscal 2018
Executive Total
Dr. Carlo de Notaristefani $7,242,520
Dr. Hafrun Fridriksdottir $5,975,031
Michael McClellan $4,946,010
Fiscal 2017
Executive Total
Dr. Carlo de Notaristefani $4,462,359
Dr. Hafrun Fridriksdottir $3,708,842
Michael McClellan $1,104,173
Key facts CIK 818686 CUSIP 881624209 13F (30d) 156 filings 144 filers Visit website Investor relations